Skip to content

Cytokinetics

US · CYTK #1564 by market cap Listed 1970
50.78 -0.68 -1.32%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 50.61 -1.65%
After-hours 52.48 +3.35%
87.2650.7850.782026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CYTK?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -27.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 100.0% Better than 99%
Operating margin -695.4% Better than 3%
Net margin -891.6% Better than 3%
Return on equity -572.1% Better than 1%
Return on invested capital -60.4% Better than 5%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -33.9% Better than 14%
6-month return -34.0% Better than 15%
12-month return (ex latest month) -4.8% Better than 27%
Distance below 52-week high 42.5% Better than 26%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.5x Better than 84%
Debt to assets 90.2% Better than 2%
Interest coverage -6.6x Better than 15%
Free cash flow / net income 215.1% Better than 79%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 93.8% Better than 76%
Upside to average target 111.3% Better than 86%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -9.53%
1M -20.59%
3M -34.21%
6M -35.53%
YTD -20.08%
1Y -20.03%
3Y +57.16%
5Y +24.28%

Key statistics

Price & volume

Prev close
51.46
Open
51.27
Day range
50.60 - 53.45
Avg price
51.42
Volume
1.43M
Turnover
73.51M
Amplitude
5.54%
52-week range
50.32 - 88.31

Valuation

P/E
-7.76
P/E (TTM)
-8.44
P/B
-22.02
EPS
-6.54
Net profit
-911.04M
Net assets
-321.23M

Share structure

Market cap
7.07B
Float cap
7.05B
Shares out
139.30M
Float shares
138.78M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 1% of range
50.32 88.31

42.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-28.46M net over the window

Short interest

Shares short
17.93M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Cytokinetics (CYTK)?

Cytokinetics last traded at 50.78. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Cytokinetics's market cap?

About 7.07B.

What is the P/E ratio of Cytokinetics?

The trailing twelve-month P/E is -8.44. The Valuation tab shows it against the stock's own five-year range.

Does Cytokinetics pay a dividend?

Cytokinetics does not currently pay a regular dividend.

Is Cytokinetics a buy according to analysts?

The consensus of 16 analysts is a Buy rating, with an average 12-month price target of 107.29, which implies 111.3% upside from the current price. This is not investment advice.

What is Cytokinetics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Cytokinetics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.

Cytokinetics discussion 0 comments

Add a comment